Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor

Jae Heon Jeong, Byoung Chul Cho, Hyo Sup Shim, Hye Ryun Kim, Sun Min Lim, Se Kyu Kim, Kyung Young Chung, S. M. Bakhtiar Ul Islam, Jae Jin Song, Soo Youl Kim, Joo Hang Kim

    Research output: Contribution to journalArticle

    11 Scopus citations

    Abstract

    Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-B). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-B expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-B expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-B value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinumbased doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P = 0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P = 0.013). Similarly, in EGFR wild-type patients treatedwith EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P = 0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI

    Original languageEnglish (US)
    Pages (from-to)1005-1014
    Number of pages10
    JournalJournal of Korean medical science
    Volume28
    Issue number7
    DOIs
    StatePublished - Jul 2013

      Fingerprint

    Keywords

    • Lung Neoplasms
    • NF-B
    • Transglutaminase 2

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Jeong, J. H., Cho, B. C., Shim, H. S., Kim, H. R., Lim, S. M., Kim, S. K., Chung, K. Y., Bakhtiar Ul Islam, S. M., Song, J. J., Kim, S. Y., & Kim, J. H. (2013). Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor. Journal of Korean medical science, 28(7), 1005-1014. https://doi.org/10.3346/jkms.2013.28.7.1005